708 related articles for article (PubMed ID: 25444674)
21. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
[TBL] [Abstract][Full Text] [Related]
24. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
25. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
[TBL] [Abstract][Full Text] [Related]
27. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Ourghanlian C; Soroka D; Arthur M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
[TBL] [Abstract][Full Text] [Related]
28. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
McLeod SM; Patey SA; Huband MD; Nichols WW
Int J Antimicrob Agents; 2017 Apr; 49(4):437-442. PubMed ID: 28242258
[TBL] [Abstract][Full Text] [Related]
29.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
30. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
Flamm RK; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
[TBL] [Abstract][Full Text] [Related]
31. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
32. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
36. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
38.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
39. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
40. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
